실시간
FierceBiotechAstraZeneca scraps FLAP inhibitor after flunking phase 2 asthma trialFierceBiotechRising costs push GE HealthCare to cut outlook as it restructures units and leadershipFierceBiotechTeva inks $700M Emalex buyout to bag near-approval Tourette drugFierceBiotechAstraZeneca restarts £300M investment in UK, but Merck not budgingCellSpatial organization and detection of social odors in mouse primary olfactory systemCellUnbiased niche labeling maps immune-excluded niche in bone metastasisCellA spatial code governs olfactory receptor choice and aligns sensory maps in the nose and brainCellErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imagingCellSensing endoplasmic reticulum redox state by ethylene receptorsBioPharma DiveChiesi to buy KalVista in $1.9B deal for rare disease drugEndpoints NewsBristol Myers reaches a crossroads as a make-or-break year takes shapeEndpoints NewsPfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenue
BioPharma Dive 2026년 4월 29일

Chiesi to buy KalVista in $1.9B deal for rare disease drug

Chiesi to buy KalVista in $1.9B deal for rare disease drug

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.